HK1254835A1 - 葡萄糖攝取抑制劑 - Google Patents

葡萄糖攝取抑制劑 Download PDF

Info

Publication number
HK1254835A1
HK1254835A1 HK18113929.9A HK18113929A HK1254835A1 HK 1254835 A1 HK1254835 A1 HK 1254835A1 HK 18113929 A HK18113929 A HK 18113929A HK 1254835 A1 HK1254835 A1 HK 1254835A1
Authority
HK
Hong Kong
Prior art keywords
glucose uptake
compounds
transporters
certain embodiments
formula
Prior art date
Application number
HK18113929.9A
Other languages
English (en)
Chinese (zh)
Inventor
K‧奥尔塞夫斯基
K‧奧爾塞夫斯基
J-I‧金
M‧波于罗夫斯基
K‧刘
A‧巴索蒂
M‧波于羅夫斯基
K‧莫里斯
K‧劉
Original Assignee
卡德门企业有限公司
卡德門企業有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 卡德门企业有限公司, 卡德門企業有限公司 filed Critical 卡德门企业有限公司
Publication of HK1254835A1 publication Critical patent/HK1254835A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18113929.9A 2015-06-26 2016-06-24 葡萄糖攝取抑制劑 HK1254835A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185223P 2015-06-26 2015-06-26
US62/185,223 2015-06-26
PCT/US2016/039365 WO2016210330A1 (en) 2015-06-26 2016-06-24 Glucose uptake inhibitors

Publications (1)

Publication Number Publication Date
HK1254835A1 true HK1254835A1 (zh) 2019-07-26

Family

ID=57586425

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113929.9A HK1254835A1 (zh) 2015-06-26 2016-06-24 葡萄糖攝取抑制劑

Country Status (8)

Country Link
US (2) US10273248B2 (enExample)
EP (1) EP3313825A4 (enExample)
JP (1) JP2018518518A (enExample)
CN (1) CN108349910A (enExample)
CA (1) CA3028355A1 (enExample)
EA (1) EA201890153A1 (enExample)
HK (1) HK1254835A1 (enExample)
WO (1) WO2016210330A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3573992B1 (en) * 2017-01-26 2022-04-13 Youla S. Tsantrizos Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof
WO2018201006A1 (en) * 2017-04-28 2018-11-01 Kadmon Corporation, Llc Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
US10329282B2 (en) 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN111217797B (zh) 2017-06-30 2021-02-05 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
US10933061B2 (en) 2017-12-21 2021-03-02 Shepherd Therapeutics, Inc. Pyrvinium pamoate therapies and methods of use
US10689386B2 (en) 2018-03-07 2020-06-23 Duquesne University Of The Holy Spirit Pyrazolo[4,3-d]pyrimidines as antitumor agents
WO2020005935A1 (en) * 2018-06-25 2020-01-02 Kadmon Corporation, Llc Glucose uptake inhibitors
US20230084927A1 (en) * 2019-11-13 2023-03-16 Metabomed Ltd. Glucose uptake inhibitors and uses thereof
JP7480298B2 (ja) * 2019-12-02 2024-05-09 シャンハイ インリー ファーマシューティカル カンパニー リミテッド 酸素含有複素環化合物、その製造方法及び使用
US20230257376A1 (en) * 2020-07-14 2023-08-17 Wuhan Ll Science And Technology Development Co., Ltd. Rock inhibitor, and preparation method therefor and use thereof
CN112479913A (zh) * 2020-11-19 2021-03-12 安徽修一制药有限公司 一种n,n-二乙基氯代乙酰胺的制备方法
CN112741828B (zh) * 2021-01-08 2022-04-26 武汉大学 药物联用物及其制备方法和用途
US20240109868A1 (en) * 2022-08-29 2024-04-04 Miracure Biotechnology Limited Ep300/cbp modulator, preparation method therefor and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60320933D1 (de) * 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
WO2009079412A2 (en) * 2007-12-14 2009-06-25 Ardea Biosciences Inc. Reverse transcriptase inhibitors
KR20120114224A (ko) * 2009-10-12 2012-10-16 마이렉시스 인코포레이티드 Ｉｋｋ 엡실론 및/또는 ｔｂｋ１의 억제제로서의 아미노-피리미딘 화합물
WO2012040499A2 (en) * 2010-09-22 2012-03-29 Surface Logix, Inc. Metabolic inhibitors
AU2012244550C1 (en) * 2011-04-21 2017-06-22 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
CN102901456B (zh) 2012-09-12 2015-10-28 深圳深蓝精机有限公司 检测装置及检测圆轴的外径、跳动值、真圆度的方法
US9815820B2 (en) * 2012-10-05 2017-11-14 Kadmon Corporation, Llc Rho kinase inhibitors
US10729691B2 (en) * 2015-06-26 2020-08-04 Kadmon Corporation, Llc Treatment of infectious diseases with glucose uptake inhibitors

Also Published As

Publication number Publication date
EA201890153A1 (ru) 2018-06-29
US10988484B2 (en) 2021-04-27
WO2016210330A1 (en) 2016-12-29
EP3313825A1 (en) 2018-05-02
US20180298029A1 (en) 2018-10-18
CN108349910A (zh) 2018-07-31
CA3028355A1 (en) 2016-12-29
JP2018518518A (ja) 2018-07-12
US10273248B2 (en) 2019-04-30
US20190315772A1 (en) 2019-10-17
EP3313825A4 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
HK1254835A1 (zh) 葡萄糖攝取抑制劑
MX2022015631A (es) Anticuerpos anti-cd40 humanizados y usos de los mismos.
AU2017319323A8 (en) Biaryl compounds useful as immunomodulators
HK1255039A1 (zh) 对pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
MY175845A (en) Substituted benzamides for treating arthropodes
WO2017100726A8 (en) Methods for treating huntington's disease
MX2016011898A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
EA201890218A1 (ru) Ретиноидные композиции для местного применения
AU2014247175A8 (en) Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use
EP4414030A3 (en) Treatment of fragile x syndrome with cannabidiol
NZ710444A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
NZ707859A (en) Inhibitors of sodium glucose cotransporter 1
EP4154714A3 (en) Fungicidal compositions
MY184628A (en) Afucosylated anti-fgfr2iiib antibodies
AU2014233478A8 (en) Anti-CD25 antibodies and their uses
MX2016004946A (es) Procesos para la preparacion de compuestos plaguicidas.
WO2017136731A8 (en) Rapaglutins, novel inhibitors of glut and use thereof
EA201692525A1 (ru) Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов
BR112012018153A2 (pt) Gel de óleo
WO2014179567A3 (en) Methods and compositions for treating beta-thalassemia and sickle cell disease
HK1220212A1 (zh) 抗cd25抗体及其用途
MX2022007671A (es) Compuestos antihelminticos que comprenden una estructura de azaindoles.
EA201692289A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов